Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Retained Earnings (2018 - 2025)

China SXT Pharmaceuticals has reported Retained Earnings over the past 8 years, most recently at -$766991.0 for Q3 2025.

  • For Q3 2025, Retained Earnings fell 34.83% year-over-year to -$766991.0; the TTM value through Sep 2025 reached -$766991.0, down 34.83%, while the annual FY2025 figure was -$1.1 million, 95.65% up from the prior year.
  • Retained Earnings for Q3 2025 was -$766991.0 at China SXT Pharmaceuticals, up from -$1.1 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $956142.0 in Q1 2022 and troughed at -$24.7 million in Q1 2024.
  • A 5-year average of -$4.8 million and a median of -$773193.0 in 2022 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: skyrocketed 1477.1% in 2021 and later plummeted 2360.45% in 2023.
  • Year by year, Retained Earnings stood at $758820.0 in 2021, then plummeted by 202.71% to -$779395.0 in 2022, then tumbled by 30.72% to -$1.0 million in 2023, then skyrocketed by 44.17% to -$568853.0 in 2024, then plummeted by 34.83% to -$766991.0 in 2025.
  • Business Quant data shows Retained Earnings for SXTC at -$766991.0 in Q3 2025, -$1.1 million in Q1 2025, and -$568853.0 in Q3 2024.